SHANGHAI XNG (03666) received the guidance to resume trading from the Hong Kong Stock Exchange and will continue to be suspended.
Shanghai Xiaonanguo (03666) announced that on May 13, 2026, the company received a letter from the Stock Exchange, which included the following resumption guidelines for the resumption of trading of the company's shares: (i) publish all financial performance that has not been disclosed in accordance with the listing rules and deal with any audit revisions; (ii) demonstrate compliance with Rule 13.24; (iii) comply again with Rules 3.10(1), 3.10A, 3.21, and 3.25; and (iv) disclose all important information to the market for shareholders and other investors to evaluate the company's situation.
SHANGHAI XNG (03666) announces that on May 13, 2026, the company received a letter from the Stock Exchange, which set out the following resumption of trading guidance for the company's shares: (i) publish all outstanding financial performance in accordance with the Listing Rules and address any audit revisions; (ii) demonstrate compliance with Rule 13.24; (iii) comply again with Rules 3.10(1), 3.10A, 3.21 and 3.25; and (iv) disclose all important information to the market for shareholders and other investors to assess the company's situation.
Under Listing Rule 6.01A(1), the Stock Exchange may delist any securities that have been suspended from trading for 18 consecutive months. For the company, this 18-month period will expire on September 30, 2027. If the company fails to remedy the issues that led to its trading suspension, comply with the resumption guidance, and fully comply with the Listing Rules to satisfy the Stock Exchange, and if it does not resume trading of its shares before September 30, 2027, the Listing Division will recommend the delisting of the company. Under Listing Rules 6.01 and 6.10, the Stock Exchange also has the right to give a shorter specified remediation period or immediately cancel the company's listing status in appropriate circumstances.
The company must disclose quarterly updates on its developments in accordance with Listing Rule 13.24A. The company must publish its first quarterly update by June 30, 2026, and subsequently every three months from June 30, 2026, until the resumption of trading or delisting (whichever is earlier).
The company must devise a resumption plan (without the need for prior approval from the Stock Exchange) and timetable, outlining the actions it deems appropriate to comply with the resumption guidance accepted by the Stock Exchange, comply with the Listing Rules, act according to the plan, and publish quarterly update information as mentioned above.
The company is taking necessary measures to comply with the resumption guidance, remedy the issues that led to its suspension of trading, and abide by the Listing Rules to satisfy the Stock Exchange and seek to resume trading of its shares as soon as possible.
The company will make further announcements in accordance with the Listing Rules at the appropriate time to provide updates to its shareholders and potential investors on the latest progress in complying with the resumption guidance.
Trading of the company's shares remains suspended.
Related Articles

US Stock Market Move | The phase III trial of melanoma drug did not reach the primary endpoint, causing Regeneron Pharmaceuticals, Inc. (RENG.US) to drop more than 10% in early trading.

AIM VACCINE (06660): Wen Jie Resigns as Independent Non-executive Director.

CH BIOTECH SER (08037) intends to sell the entire equity of Standard Pathology Laboratory and Jockey Health for a total of HK$3.5 million
US Stock Market Move | The phase III trial of melanoma drug did not reach the primary endpoint, causing Regeneron Pharmaceuticals, Inc. (RENG.US) to drop more than 10% in early trading.

AIM VACCINE (06660): Wen Jie Resigns as Independent Non-executive Director.

CH BIOTECH SER (08037) intends to sell the entire equity of Standard Pathology Laboratory and Jockey Health for a total of HK$3.5 million






